Nautilus Biotechnology (NAUT) Change in Accured Expenses (2020 - 2026)
Nautilus Biotechnology (NAUT) reported Change in Accured Expenses of $128000.0 for Q1 2026, down 75.62% on a YoY basis from $525000.0 in Q1 2025, and up 118.21% sequentially from -$703000.0 in Q4 2025.
Nautilus Biotechnology (NAUT) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Nautilus Biotechnology (NAUT) has 7 years of Change in Accured Expenses data on file, last reported at $128000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 75.62% year-over-year to $128000.0; the trailing twelve-month figure through Mar 2026 stood at $232000.0 (up 138.41% YoY), and the FY2025 full-year result was $629000.0, up 145.03% from the prior year.
- Change in Accured Expenses grew to $128000.0 in Q1 2026, from -$703000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $942000.0 in Q3 2025 to a low of -$703000.0 in Q4 2025.
- A 5-year average of $10941.2 and a median of -$135000.0 in 2025 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses sank 512.31% in 2024 and surged 4195.65% in 2025, its largest moves.
- Tracing NAUT's Change in Accured Expenses over 5 years: stood at -$451000.0 in 2022, then gained by 24.61% to -$340000.0 in 2023, then sank by 96.47% to -$668000.0 in 2024, then decreased by 5.24% to -$703000.0 in 2025, then soared by 118.21% to $128000.0 in 2026.
- Business Quant data shows NAUT's Change in Accured Expenses at $128000.0 in Q1 2026, -$703000.0 in Q4 2025, and $942000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | Nautilus Biotechnology | 212.11 Mn | 116.24 Mn | - | 128,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 128,000.00 |
| Mar 31, 2026 | 128,000.00 |
| Dec 31, 2025 | -703,000.00 |
| Dec 31, 2025 | -703,000.00 |
| Sep 30, 2025 | 942,000.00 |
| Sep 30, 2025 | 942,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Mar 31, 2025 | 525,000.00 |
| Mar 31, 2025 | 525,000.00 |
| Dec 31, 2024 | -668,000.00 |
| Dec 31, 2024 | -668,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -438,000.00 |
| Jun 30, 2024 | -438,000.00 |
| Mar 31, 2024 | -268,000.00 |
| Mar 31, 2024 | -268,000.00 |
| Dec 31, 2023 | -340,000.00 |
| Dec 31, 2023 | -340,000.00 |